Early-Onset Disease Often Requires a Different Diagnostic Lens
Children diagnosed with inflammatory bowel disease before age 6 represent a distinct clinical population. Compared with older pediatric patients, very early onset inflammatory bowel disease (VEO-IBD) has been associated with higher rates of severe disease, early therapy resistance, and underlying immune-mediated or genetic disorders that may not be identified through standard pediatric IBD evaluation pathways. Identification of an underlying immune or genetic diagnosis can alter treatment selection, surveillance strategies, family counseling, and long-term prognosis.
For community gastroenterologists and pediatric subspecialists, recognizing when disease presentation falls outside typical IBD patterns can have important implications for diagnosis, treatment selection and long-term management. Patients with atypical clinical features, unusual histopathology, severe disease burden or poor response to conventional therapies may warrant expanded evaluation for immune dysfunction or monogenic disease.
Coordinated Subspecialty Evaluation Helps Identify Underlying Disease Drivers
To address the complexity of these patients, Cincinnati Children's has developed a dedicated Very Early Onset IBD Clinic led by pediatric gastroenterologist Jasbir (Jazz) Dhaliwal, MD MSc, MRCPCH, whose clinical and research focus centers on precision medicine approaches for complex inflammatory bowel disease.
The clinic is structured around a multidisciplinary model that brings together pediatric gastroenterology, immunology, genetics, pathology, dietetics, dermatology, radiology, surgery and social work within a coordinated clinical pathway. Rather than conducting evaluations in isolation, specialists review findings collectively and incorporate them into a unified care plan.
This approach is designed to help identify underlying disease mechanisms that may not be apparent through conventional evaluation alone and to ensure that diagnostic findings translate directly into management decisions.
Targeted Genetic and Immune Testing Can Inform Treatment Decisions
For patients with early-onset disease, atypical presentations, or refractory symptoms, the clinic incorporates targeted immune and genetic assessments when clinically indicated. These evaluations may identify immune dysregulation or monogenic variants that influence both prognosis and therapeutic strategy.
Diagnostic testing is coordinated within the clinical visit to reduce redundancy and facilitate efficient interpretation of results across specialties. Treatment plans are then individualized with goals that extend beyond disease control to include optimization of growth, nutrition and developmental outcomes. Referring physicians remain involved in longitudinal management whenever appropriate.
Referral May Be Appropriate Before Conventional Pathways Are Exhausted
The VEO-IBD Clinic serves as a referral and second-opinion resource for clinicians caring for children with:
- IBD diagnosed before age 6
- Severe or treatment-refractory disease
- Atypical clinical or histologic findings
- Concern for immune-mediated or monogenic disease
Timely referral may help clarify diagnosis, identify underlying disease mechanisms and support treatment planning before additional therapeutic escalation is pursued. Recommendations are communicated directly back to referring providers to support ongoing co-management.
Refer a Patient or Discuss a Complex Case
Physicians seeking multidisciplinary evaluation, second opinions or co-management support for patients with suspected VEO-IBD, immune-mediated intestinal disease or possible monogenic IBD can contact the Cincinnati Children's VEO-IBD Clinic.
Looking Ahead
As the understanding of immune dysregulation and monogenic contributors to pediatric IBD continues to expand, precision medicine approaches are becoming increasingly relevant for children with very early onset disease. Integrating gastroenterology, immunology and genetics into a coordinated evaluation pathway may help clinicians move beyond symptom-based treatment algorithms toward more individualized management strategies for this complex patient population.
(Published April 2026)
